Rôles Des Récepteurs Nucléaires Nur77 Et Nor-1 Et Des

Total Page:16

File Type:pdf, Size:1020Kb

Rôles Des Récepteurs Nucléaires Nur77 Et Nor-1 Et Des Rôles des récepteurs nucléaires Nur77 et Nor-1 et des neuropeptides enképhaline et dynorphine dans les comportements médiés par la dopamine et induits par les psychostimulants Thèse Céline Hodler Programme de doctorat en Neurobiologie Philosophiae doctor (Ph.D.) Faculté de médecine Québec, Canada © Céline Hodler, 2012 RÉSUMÉ Cette thèse démontre que les récepteurs nucléaires Nur77 et Nor-1 ainsi que les neuropeptides dynorphine (DYN) et enképhaline (ENK) sont des facteurs déterminants de la régulation du système dopaminergique. Notre premier manuscrit démontre d’une part que Nur77 et Nor-1 sont très clairement impliqués dans la régulation de l’homéostasie du système dopaminergique et qu’ils y jouent des rôles distincts, voire opposés, dans les conditions basales et dans les réponses comportementales et biochimiques aux psychostimulants. La délétion génétique de Nur77 augmente la proportion des récepteurs D2 en haute affinité (D2high), supprime les stéréotypies et perturbe la persistance de la préférence de place induites par l’administration répétée de psychostimulants. À l’inverse, la délétion de Nor-1 diminue la proportion des récepteurs D2high, atténue les comportements moteurs en réponse à l’amphétamine et supprime la sensibilisation comportementale. La délétion de Nor-1 module également l’expression de la DYN et de l’ENK favorisant ainsi une diminution de la réponse comportementale alors que celle de Nur77 induit l’effet inverse. Ainsi, Nor-1 et Nur77 jouent des rôles opposés, la délétion de Nor-1 tempère les comportements moteurs, celle de Nur77 les exacerbe. Notre second manuscrit démontre d’autre part que la DYN et l’ENK sont toutes deux nécessaires et ont des rôles opposés dans la manifestation des comportements de base médiés par la dopamine. Par contre, dans les conditions d’une exposition répétée aux psychostimulants, la DYN et l’ENK agissent de concert en potentialisant l’exacerbation de l’activité locomotrice et sont donc toutes deux indispensables à la sensibilisation comportementale. Nos travaux révèlent également l’existence d’interactions entre les neurotransmissions enképhalinergique et dynorphinergique et donc entre les deux voies de sortie indirecte et directe des ganglions de la base. Aussi, les neuropeptides DYN et ENK sont modulés différentiellement par la délétion de Nur77 et de Nor-1 et inversement leur délétion régule de manière différente l’expression de ces facteurs de transcription. Ceci suggère l’existence d’une relation de régulation réciproque entre les récepteurs nucléaires et ces neuropeptides. Nur77 et Nor-1 sont donc des régulateurs clés de la transmission dopaminergique et des réponses comportementales aux psychostimulants et ce, principalement via la modulation des récepteurs dopaminergiques et des neuropeptides striataux. I ABSTRACT This present study demonstrates that the nuclear receptors Nur77 and Nor-1 and the neuropeptides dynorphin (DYN) and enkephalin (ENK) are crucial in dopaminergic system regulation. On one hand, our first manuscript shows that Nur77 and Nor-1 are deeply involved in the homeostatic regulation of the dopaminergic system and play distinct, mostly opposite roles, in basal dopaminergic neurotransmission and in psychostimulants-induced behavioral and biochemical effects. In particular, Nur77 deletion exacerbates the behavioral effects of both acute and chronic amphetamine (AMPH) administrations while Nor-1 deletion has the opposite effect. In fact, Nur77 deletion favors the upregulation of the proportion of D2 receptors in high affinity state (D2high) and suppress AMPH-induced stereotyped behavior. On the contrary, Nor-1 deletion downregulates the D2high receptors proportion, attenuates locomotor activity in response to chronic AMPH administration and consequently suppresses the development of behavioral sensitization. Nor-1 deletion modulates DYN and ENK expression in a way that promotes decreased behavioral responses to psychostimulants and that is opposite to the effects of Nur77 deletion on these very same neuropeptides. Also, Nur77 deletion suppresses the persistance of cocaine- induced place preference wherese Nor-1 deletion has no effect. Thus, Nor-1 and Nur77 mostly play opposite roles, Nor-1 deletion dampens ambulatory activity whereas Nur77 deletion exacerbates it. On the other hand, our second manuscript shows that DYN and ENK are both necessary and play opposite roles in dopamine-mediated basal behaviors. However, during chronic psychostimulants exposure, DYN and ENK both contribute to the exacerbation of locomotor activity and they are consequently both essential for the expression of behavioral sensitization. Besides, our results highlight a cross-talk between ENK and DYN neurotransmissions and thus between the indirect and direct output pathways of the basal ganglia. Interestingly, we also show that the striatal DYN and ENK deletions could differentially modulate Nur77 et Nor-1 expression. This suggests that the nuclear receptors and the neuropeptides ENK and DYN share an intimate reciprocal regulation relationship. Collectively, our results strongly establish that Nur77 and Nor-1 are key regulators of the dopaminergic neurotransmission and of behavioral responses to psychostimulants and this, mostly via the modulation of dopaminergic receptors and striatal neuropeptides. II AVANT-PROPOS Je tiens à remercier, en premier lieu, mon directeur et mon co-directeur de recherche, les Drs Claude Rouillard et Daniel Lévesque. Ce fut un privilège d'avoir pu travailler avec ces chercheurs compétents, passionnés et généreux. Merci pour votre soutien, vos encouragements, votre confiance, votre précieuse expérience et votre disponibilité. Avant tout, Claude, merci de m’avoir accordé ta confiance et de m'avoir donné la chance de travailler à tes côtés à la maîtrise puis au doctorat. Merci aussi pour ton soutien financier qui m'a permis de m'investir pleinement dans mes études. Merci pour ton encadrement bienveillant. J'ai tiré un grand plaisir de nos discussions au laboratoire, et je tiens en particulier à t’exprimer ma gratitude pour tes conseils avisés, tes encouragements, ton réconfort et ta compréhension lors de mes moments de fragilité et d’incertitude. Tu as contribué à rendre plus lumineuses et prometteuses mes années au Québec grâce à ton écoute et à ton soutien dans mes projets professionnels. Un immense merci à Brigitte Paquet, premièrement pour m'avoir assistée et formée pendant toutes ces années. Deuxièmement, et de façon encore plus significative à mes yeux, merci pour toutes ces petites attentions qui ont su égailler mes journées. Merci à tous mes amis et collaborateurs, je pense à, Joanie Baillargeon, Aurore Voisin, Emmanuelle Bourhis, Cécile Vue, Jérôme Maheux, Michel st-Hilaire, François Gilbert, Marc Cloutier. Un merci tout spécial à Emmanuelle Berret et Antoine Hone-Blanchet, vos personnalités joyeuses et votre esprit plaisantin ont su me motiver dans les moments de découragement. Merci pour votre aide précieuse et votre amitié. Vous avez tous été d’une aide essentielle pour l’élaboration et l’aboutissement de mon projet de recherche. J'aimerais aussi remercier mes parents, Marie-Claire et Jürg, pour m’avoir soutenu financièrement pendant mes études. Merci surtout à mes frères, David et Manuel, pour leur présence réconfortante, leur complicité, leur humour imparable et leur amour inconditionnel qui m’ont été indispensables et salutaires dans les moments difficiles. III Bien que je sois première auteure des deux articles composant les chapitres 2 et 3 de cette thèse, j'ai bénéficié de la collaboration de plusieurs de mes collègues et, bien évidemment, des Drs Claude Rouillard et Daniel Lévesque. Le chapitre 2 de ma thèse, « Distinct roles for the nuclear receptors Nur77 and Nor- 1 in dopamine-mediated and psychostimulant-induced behaviors », est un article en voie de soumission dans un journal international de haut calibre. J'ai été directement impliqué dans toutes les étapes qui ont menées à la réalisation de cette étude. J'ai effectué tous les traitements et quantifications des comportements chez les souris. J'ai également réalisé les perfusions et prélèvements des cerveaux. J’ai aussi effectué toutes les hybridations in situ. J'ai également procédé à la quantification et l'analyse statistique des résultats. La rédaction de l'article a été réalisée par moi-même et révisée par le Dr. Claude Rouillard. Antoine Hone-blanchet, est présenté comme second auteur car il m’a fourni les données biochimiques concernant l’expression de la DYN suite à l’administration aigüe d’amphétamine chez les souris Nur77 (-/-). Joanie Baillargeon et Brirgitte Paquet, nos deux assistantes de recherche, ont aidé à la quantification de certains protocoles et m’ont assistée lors des chirurgies. Le Dr. Philip Seeman m’a fourni les données concernant le pourcentage d’expression des récepteurs D2 en haute affinité. Le Dr. Daniel Lévesque a, avec le Dr. Claude Rouillard, participé à l'élaboration des hypothèses de recherche, à la mise sur pied des protocoles expérimentaux, ainsi qu’à la correction de l'article. Le chapitre 3, «Implication of the endogenous striatal neuropeptides Enkephalin and Dynorphin in dopamine-mediated and psychostimulant-induced behaviors.», est un article en voie de soumission dans un journal international. Dans cette étude, Brigitte Paquet m’a assistée pour la réalisation des expériences comportementales, et notamment lors de l'administration des traitements. J’ai réalisé les techniques d'hybridation in situ, la quantification, l'analyse et l'interprétation
Recommended publications
  • Behavioral and Brain Sciences Plasticity: Implications for Opioid
    Behavioral and Brain Sciences http://journals.cambridge.org/BBS Additional services for Behavioral and Brain Sciences: Email alerts: Click here Subscriptions: Click here Commercial reprints: Click here Terms of use : Click here Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Behavioral and Brain Sciences / Volume 20 / Issue 03 / September 1997, pp 392 ­ 403 DOI: null, Published online: 08 September 2000 Link to this article: http://journals.cambridge.org/abstract_S0140525X97241488 How to cite this article: Anthony H. Dickenson (1997). Plasticity: Implications for opioid and other pharmacological interventions in specific pain states. Behavioral and Brain Sciences,20, pp 392­403 Request Permissions : Click here Downloaded from http://journals.cambridge.org/BBS, IP address: 144.82.107.43 on 10 Aug 2012 BEHAVIORAL AND BRAIN SCIENCES (1997) 20, 392±403 Printed in the United States of America Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Department of Pharmacology, University College London, London WC1E 6BT, United Kingdom Electronic mail: anthony.dickenson6ucl.ac.uk Abstract: The spinal mechanisms of action of opioids under normal conditions are reasonably well understood. The spinal effects of opioids can be enhanced or reduced depending on pathology and activity in other segmental and nonsegmental pathways. This plasticity will be considered in relation to the control of different pain states using opioids. The complex and contradictory findings on the supraspinal actions of opioids are explicable in terms of heterogeneous descending pathways to different spinal targets using multiple transmitters and receptors ± therefore opioids can both increase and decrease activity in descending pathways.
    [Show full text]
  • Cardioprotective Properties of Opioid Receptor Agonists in Rats with Stress-Induced
    Cardioprotective Properties of Opioid Receptor Agonists in Rats with Stress-Induced Cardiac Injury Ekaterina S. Prokudinaa B, Leonid N. Maslova* A, D, E, F, Natlia V. Naryzhnayaa B,G, Sergey Yu. Tsibulnikova B,C,E, Yury B. Lishmanova,b D, John E. Madias PhD c D,E, Peter R. Oeltgen PhD d D,E aLaboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences 634012 Tomsk, Russia. bLaboratory of Nuclear Medicine, National Research Tomsk Polytechnic University, Tomsk, Russia. cIcahn School of Medicine at Mount Sinai, and the Division of Cardiology, Elmhurst Hospital Center, New York, New York, USA. dDepartment of Pathology, University of Kentucky College of Medicine, Lexington, KY, USA * Correspondence: Leonid N. Maslov, MD, PhD, DSci, Professor of Pathological Physiology Laboratory of Experimental Cardiology, Federal State Budgetary Scientific Institution «Research Institute for Cardiology», Kyevskaya 111A, 634012 Tomsk, Russia Tel. +7 3822 262174 E-mail address: [email protected] Short title: Stress cardiomyopathy and opioid receptors Summary Purpose The objectives of this study were to investigate the role of endogenous opioids in the mediation of stress-induced cardiomyopathy (SIC), and to evaluate which opioid receptors regulate heart resistance to immobilization stress. Methods Wistar rats were subjected to 24 h 1 immobilization stress. Stress-induced heart injury was assessed by 99mTc-pyrophosphate accumulation in the heart. The opioid receptor (OR) antagonists (naltrexone, NxMB - naltrexone methyl bromide, MR 2266, ICI 174.864) and agonists (DALDA, DAMGO, DSLET, U-50,488) were administered intraperitoneally prior to immobilization and 12 h after the start of stress. In addition, the selective µ OR agonists PL017 and DAMGO were administered intracerebroventricularly prior to stress.
    [Show full text]
  • Morphine Indiscriminatingly Overstimulates All Opioid Receptors Including Those Not Involved in (Morphine) Pain Control (Exogenous)
    Extensions des propriétés des inhibiteurs mixtes des enképhalinases aux douleurs de la sphère cranio-faciale. Nouvelles applications à la migraine et aux douleurs de la cornée. Bernard P. Roques Professeur Emérite, Université Paris Descartes Unité 1267 Inserm, 4 avenue de l’Observatoire, 75006 Paris. ATHS Biarritz, 1-4 Octobre 2019 CONFIDENTIAL 1 Endorphins and their receptors. Endomorphin-1 Tyr – Pro – Trp – Phe – NH2 Endomorphin-2 Tyr – Pro – Phe – Phe – NH2 2 2 Drug Discovery : designing the ideal opioid (From B.L. Kieffer, Nature (2016), 537, 170-171) 3 Three levels of pain control by endogenous opioid system (EOS) EOS EOS Attacking pain at EOS its source Relieving or reducing pain at its source More than 50% of MO effects are attributable to peripheral neurons (nociceptors) Roques, B.P., Fournié-Zaluski, M.C. and Wurm, M., Nature Reviews Drug Discovery, 2012 4 DENKIs: mechanism of action The endogenous opioid system (EOS) is present at all levels of physiological-nociceptive control i.e. periphery, spinal cord and brain Elements of the EOS are opioid receptors, enkephalins and their inactivating enzymes Dual Inhibitors of ENKephalinases (DENKIs) potentiate physiological functions of DENKI enkephalins (e.g. pain control) only on those pathways where they are tonically released Enkephalinases APN NEP No adverse effects Enkephalins Y G G F M(L) (endogenous) Opioid receptors Morphine indiscriminatingly overstimulates all opioid receptors including those not involved in (Morphine) pain control (exogenous) Adverse effects 5 Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets in a murine model of bone cancer-induced pain.
    [Show full text]
  • The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
    Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • (D-Ala*)Deltorphin II: D,-Dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens
    The Journal of Neuroscience, June 1991, 17(6): 1565-l 576 (D-Ala*)Deltorphin II: D,-dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens R. Longoni,’ L. Spina,’ A. Mulas,’ E. Carboni,’ L. Garau,’ P. Melchiorri,2 and G. Di Chiaral ‘Institute of Experimental Pharmacology and Toxicology, University of Cagliari, 09100 Cagliari, Italy and 21nstitute of Medical Pharmacology, University of Rome “La Sapienza,” 00185 Rome, Italy In order to investigate the relative role of central 6- and has been implicated in the stimulant actions of systemic opiates. F-opioid receptors in behavior, the effects of (D- Morphine-like opiates stimulate DA release preferentially in the Ala*)cleltorphin II, a natural Gopioid peptide, and PL017, nucleus accumbens (Di Chiara and Imperato, 1988a) and elicit a beta-casomorphin derivative specific for mu receptors, hypermotility sensitive to blockade by the DA D, receptor an- were compared after local intracerebral and intraventricular tagonist SCH 23390 (Longoni et al., 1987a). Intra-accumbens administration. lntracerebral infusion of the two peptides was infusion of opioid peptides elicits motor stimulation, but this done bilaterally in the limbic nucleus accumbens and in the action seems independent from DA, being resistant to classic ventral and dorsal caudate putamen of freely moving rats DA-receptor antagonists (neuroleptics; Pert and Sivit, 1977; Ka- through chronic intracerebral cannulas. After intra-accum- livas et al., 1983). Moreover, the syndrome elicited by intra- bens infusion, the two peptides elicited marked but opposite accumbens opiates is biphasic, as motor stimulation is typically behavioral effects: while (o-Ala2)deltorphin II evoked dose- preceded by motor inhibition and catalepsy (Costa11et al., 1978).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.247,609 B2 Roques Et Al
    USOO82476.09B2 (12) United States Patent (10) Patent No.: US 8.247,609 B2 Roques et al. (45) Date of Patent: Aug. 21, 2012 (54) AMINOACID DERIVATIVES CONTAININGA FOREIGN PATENT DOCUMENTS DSULFANYL GROUPIN THE FORM OF EP O262O53 3, 1988 MIXED DISULEANYLAND AMINOPEPTIDASEN INHIBITORS (Continued) (75) Inventors: Bernard Roques, Paris (FR): Marie-Claude Fournie-Zalluski, Paris OTHER PUBLICATIONS (FR) Silverman (The Organic Chemistry of Drug Design and Drug Action, (73) Assignee: Pharamleads, Paris (FR) 1992, Academic Press Inc.).* (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 U.S.C. 154(b) by 868 days. (21) Appl. No.: 12/146,941 Primary Examiner — Susanna Moore Assistant Examiner — Jennifer C Sawyer (22) Filed: Jun. 26, 2008 (74) Attorney, Agent, or Firm — Harness, Dickey & Pierce, (65) Prior Publication Data P.L.C. US 2009/OO12153 A1 Jan. 8, 2009 Related U.S. Application Data (57) ABSTRACT (63) Continuation-in-part of application No. 12/084,091, The invention relates to novel compounds of formula (I): filed as application No. PCT/EP2006/067711 on Oct. HN CH(R)-CH S S CH-CH(R) CONH 24, 2006. Rs, wherein R is a hydrocarbon chain, phenyl or benzyl (30) Foreign Application Priority Data radical, methylene radical substituted by a 5 or 6 atom het erocycle; R is a phenyl or benzyl radical, a 5 or 6 atom Oct. 25, 2005 (FR) ...................................... O5 10862 aromatic heterocycle, methylene group Substituted by a 5 or 6 May 5, 2006 (FR) ...................................... O6 O4030 atom heterocycle; Rs is a CH(R)—COOR radical, wherein R is hydrogen, an OH or OR group, a saturated hydrocarbon (51) Int.
    [Show full text]
  • Replacement of Current Opioid Drugs Focusing on MOR-Related Strategies
    JPT-107519; No of Pages 17 Pharmacology & Therapeutics xxx (2020) xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Replacement of current opioid drugs focusing on MOR-related strategies Jérôme Busserolles a,b, Stéphane Lolignier a,b, Nicolas Kerckhove a,b,c, Célian Bertin a,b,c, Nicolas Authier a,b,c, Alain Eschalier a,b,⁎ a Université Clermont Auvergne, INSERM, CHU, NEURO-DOL Pharmacologie Fondamentale et Clinique de la douleur, F-63000 Clermont-Ferrand, France b Institut ANALGESIA, Faculté de Médecine, F-63000 Clermont-Ferrand, France c Observatoire Français des Médicaments Antalgiques (OFMA), French monitoring centre for analgesic drugs, CHU, F-63000 Clermont-Ferrand, France article info abstract Available online xxxx The scarcity and limited risk/benefit ratio of painkillers available on the market, in addition to the opioid crisis, warrant reflection on new innovation strategies. The pharmacopoeia of analgesics is based on products that are often old and derived from clinical empiricism, with limited efficacy or spectrum of action, or resulting in Keywords: an unsatisfactory tolerability profile. Although they are reference analgesics for nociceptive pain, opioids are sub- Analgesia ject to the same criticism. The use of opium as an analgesic is historical. Morphine was synthesized at the begin- Mu opioid receptors (MORs) ning of the 19th century. The efficacy of opioids is limited in certain painful contexts and these drugs can induce Opioid adverse side effects potentially serious and fatal adverse effects. The current North American opioid crisis, with an ever-rising number Opioid abuse and misuse of deaths by opioid overdose, is a tragic illustration of this.
    [Show full text]
  • Inhibiting the Breakdown of Endogenous Opioids and Cannabinoids to Alleviate Pain
    REVIEWS Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain Bernard P. Roques1,2, Marie-Claude Fournié-Zaluski1 and Michel Wurm1 Abstract | Chronic pain remains unsatisfactorily treated, and few novel painkillers have reached the market in the past century. Increasing the levels of the main endogenous opioid peptides — enkephalins — by inhibiting their two inactivating ectopeptidases, neprilysin and aminopeptidase N, has analgesic effects in various models of inflammatory and neuropathic pain. Stemming from the same pharmacological concept, fatty acid amide hydrolase (FAAH) inhibitors have also been found to have analgesic effects in pain models by preventing the breakdown of endogenous cannabinoids. Dual enkephalinase inhibitors and FAAH inhibitors are now in early-stage clinical trials. In this Review, we compare the effects of these two potential classes of novel analgesics and describe the progress in their rational design. We also consider the challenges in their clinical development and opportunities for combination therapies. Pain is a unique, conscious experience with sensory- to the market. There is an urgent need for novel treat- Fibromyalgia A disorder of unknown discriminative, cognitive-evaluative and affective- ments for all types of pain, particularly neuropathic pain, 1 aetiology that is characterized emotional components . Transient and acute pain can be that show greater efficacy, better tolerability and wider by widespread pain, abnormal effectively alleviated by activating the endogenous safety margins11. pain processing, sleep opioid system, which has a key role in discriminating One innovative approach12 for the development disturbance, fatigue and between innocuous and noxious sensations2,3. However, of analgesics is based on the fact that the painkillers often psychological distress.
    [Show full text]
  • Opioid Peptides: Medicinal Chemistry, 69
    Opioid Peptides: Medicinal Chemistry DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Opioid Peptides: Medicinal Chemistry Editors: Rao S. Rapaka, Ph.D. Gene Barnett, Ph.D. Richard L. Hawks, Ph.D. Division of Preclinical Research National Institute on Drug Abuse NIDA Research Monograph 69 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute San Francisco, California Alcohol and Drug Problems Association of North America WashIngton, DC DENISE KANDEL, Ph.D. GILBERT J. BOTVIN, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
    List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders,
    [Show full text]
  • Low Doses of Cyclic AMP-Phosphodiesterase Inhibitors
    B R A I N R E S E A R C H 1 2 3 1 ( 2 0 0 8 ) 1 6 – 2 4 ava i l a b l e a t w w w. s c i e n c e d i re c t . c o m w w w. e l s ev i e r. c o m / l o c a t e / b ra i n re s Research Report Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone Stanley M. Crain⁎, Ke-Fei Shen Department of Neuroscience, Albert Einstein College of Medicine, Yeshiva University, 1300 Morris Park Avenue, Bronx, NY 10461, USA A R T I C L E I N F O A B S T R A C T Article history: Systemic (s.c.) injection in naïve mice of cyclic AMP-phosphodiesterase (cAMP-PDE) Accepted 3 July 2008 inhibitors, e.g. 3-isobutyl-1-methylxanthine [(IBMX) or caffeine, 10 mg/kg] or the more Available online 12 July 2008 specific cAMP-PDE inhibitor, rolipram (1 μg/kg), rapidly evokes thermal hyperalgesia (lasting >5 h). These effects appear to be mediated by enhanced excitatory opioid receptor signaling, Keywords: as occurs during withdrawal in opioid-dependent mice. Cotreatment of these mice with Endogenous opioid hyperalgesia ultra-low-dose naltrexone (NTX, 0.1 ng/kg–1 pg/kg, s.c.) results in prominent opioid analgesia Endogenous opioid analgesia (lasting >4 h) even when the dose of rolipram is reduced to 1 pg/kg.
    [Show full text]
  • Discovery of Novel Opioid Medications
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Discovery of Novel Opioid Medications 147 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Discovery of Novel Opioid Medications Editors: Rao S. Rapaka, Ph.D. Heinz Sorer, Ph.D. NIDA Research Monograph 147 1995 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Discovery of Novel Opioid Medications” held on July 28-29, 1993. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]